Predicting 5-Year Progression and Survival Outcomes for Early-Stage Non-Small Cell Lung Cancer Treated with Stereotactic Ablative Radiotherapy: Development and Validation of Robust Prognostic Nomograms.

[1]  D. Sher,et al.  Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis. , 2019, Lung cancer.

[2]  W. Guo,et al.  Systemic immune‐inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non‐small cell lung cancer , 2019, Thoracic cancer.

[3]  M. Langer,et al.  Histology, Tumor Volume, and Radiation Dose Predict Outcomes in NSCLC Patients After Stereotactic Ablative Radiotherapy , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[5]  Hongdian Zhang,et al.  Preoperative increased systemic immune-inflammation index predicts poor prognosis in patients with operable non-small cell lung cancer. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[6]  Joe Y. Chang,et al.  Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer , 2018, JAMA network open.

[7]  Jinming Yu,et al.  Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. , 2018, Future oncology.

[8]  T. Mizowaki,et al.  A Retrospective Long-term Follow-up Study of Stereotactic Body Radiation Therapy for Non-Small Cell Lung Cancer From a Single Institution: Incidence of Late Local Recurrence. , 2018, International journal of radiation oncology, biology, physics.

[9]  C. Simone,et al.  Histology significantly affects recurrence and survival following SBRT for early stage non-small cell lung cancer. , 2018, Lung cancer.

[10]  G. Fontanini,et al.  Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial , 2018, JAMA oncology.

[11]  Yanqing Wang,et al.  Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients , 2018, The Prostate.

[12]  Y. Tao,et al.  A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy , 2018, The oncologist.

[13]  C. Albany.  Systemic immune-inflammation index in germ-cell tumours: search for a biological prognostic biomarker , 2018, British Journal of Cancer.

[14]  Y. Huang,et al.  Nomograms for predicting disease progression in patients of Stage I non-small cell lung cancer treated with stereotactic body radiotherapy , 2018, Japanese journal of clinical oncology.

[15]  Ya-nan Sun,et al.  Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience , 2018, Journal of Cancer.

[16]  A. Warth,et al.  Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[17]  Yu-suo Tong,et al.  Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer , 2017, Journal of Translational Medicine.

[18]  S. Cai,et al.  Prognostic value of systemic immune-inflammation index in patients with gastric cancer , 2017, Chinese journal of cancer.

[19]  P. Xia,et al.  A Histologic Basis for the Efficacy of SBRT to the lung , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  Qi Zhou,et al.  Systemic Immune-Inflammation Index Predicts Prognosis of Patients with Esophageal Squamous Cell Carcinoma: A Propensity Score-matched Analysis , 2016, Scientific Reports.

[21]  C. Gross,et al.  The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[22]  Joe Y. Chang,et al.  Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. , 2016, International journal of radiation oncology, biology, physics.

[23]  P. Kupelian,et al.  Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. , 2016, Clinical lung cancer.

[24]  Michael J Pencina,et al.  Evaluating Discrimination of Risk Prediction Models: The C Statistic. , 2015, JAMA.

[25]  C. Reddy,et al.  Predicting Overall Survival After Stereotactic Ablative Radiation Therapy in Early-Stage Lung Cancer: Development and External Validation of the Amsterdam Prognostic Model. , 2015, International journal of radiation oncology, biology, physics.

[26]  M. Berry,et al.  Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. , 2015, The Annals of thoracic surgery.

[27]  E. Ruffini,et al.  Exploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5-year survival after surgical resection†. , 2015, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[28]  H. Groen,et al.  Patterns of Recurrence and Survival after Surgery or Stereotactic Radiotherapy for Early Stage NSCLC , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  P. Iyengar,et al.  Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  R. Weichselbaum,et al.  Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. , 2015, International journal of radiation oncology, biology, physics.

[31]  W. Guo,et al.  Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma , 2014, Clinical Cancer Research.

[32]  M. Miyazaki,et al.  Dose-volume-response analysis in stereotactic radiotherapy for early lung cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[33]  Heunglae Cho,et al.  Analysis of Biologically Equivalent Dose of Stereotactic Body Radiotherapy for Primary and Metastatic Lung Tumors , 2014, Cancer research and treatment : official journal of Korean Cancer Association.

[34]  J. Sonke,et al.  Substantial Dose-response Relationship with Clinical Outcome for Lung Stereotactic Body Radiotherapy (SBRT) Delivered via Online Image Guidance , 2010 .

[35]  Suresh Senan,et al.  Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis. , 2012, The Lancet. Oncology.

[36]  John Cho,et al.  Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[37]  M. Hiraoka,et al.  Prognostic factors in stereotactic body radiotherapy for non-small-cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.

[38]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[39]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[40]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Guoqing Diao,et al.  Estimation of time‐dependent area under the ROC curve for long‐term risk prediction , 2006, Statistics in medicine.

[42]  Nils Lid Hjort,et al.  Goodness‐of‐fit processes for logistic regression: simulation results , 2002, Statistics in medicine.